Innovative transdermal oxygen therapy firm accelerates growth and product launch with clinivation’s Quality Systems infrastructure and process solutions.
Framingham, MA, November 14, 2003 – clinivation, Inc. announced today that Ogenix, Inc. has selected clinivation’s quality systems infrastructure and process solutions.
“Ogenix is the emerging leader in transdermal, sustained delivery oxygen therapy for wound care and other important medical and surgical applications,” said Joseph Kozikowski, M.D., clinivation’s Founder, Chairman, and Chief Executive Officer. “We are pleased that Ogenix’s senior management has selected clinivation to help extend their quality systems and position their manufacturing and development operations for continued growth and expansion,” he continued.
Clinivation’s rapidly-implementable quality systems infrastructure solutions are pre-configured, matched to specific client needs, and designed to scale with product history and organization growth.
About Ogenix, Inc.
Ogenix, Inc. is a medical device company dedicated to developing, manufacturing, and marketing innovative, miniature oxygen generators for wound care and other important medical and surgical applications.
Ogenix’s lead product- EpiFLO SD™– has received FDA approval for the treatment of diabetic foot ulcers, venous leg ulcers, pressure ulcers, and other important medical and surgical indications.
For more information about Ogenix, Inc., visit the Company’s Web site at www.ogenix.net
